Navigation Links
Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
Date:11/11/2013

MOSCOW, Nov. 11, 2013 /PRNewswire/ -- Executive leadership at Rafarma Pharmaceuticals (OTC:RAFA), recently met with the Governor of Lipetsk, Oleg Korolev, along with several government economic development representatives, including the Trade mission of the Russian Federation in Great Britain and announced plans for British investment in the region to create a "biopharmaceutical cluster" in Terbuny. The parties signed a project initiative to increase growth of the pharmaceutical industry in the region, finalize British investment and obtain manufacturing contracts for Rafarma and its biotech neighbors. As a certified and operating pharmaceutical manufacturer, Rafarma will be the lead company in this venture.

Governor Korolev described Rafarma as one of the best pharmaceutical enterprises of the Russian Federation, and praised the plant's full compliance with International Good Manufacturing Practices.

"Rafarma's state-of-the-art pharmaceutical plant in Terbuny has become the flashpoint for biopharma investment in Terbuny, Rafarma is leading the way," stated RAFA CEO Dave Anderson

About Rafarma Pharmaceuticals, Inc.

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

For more information on Rafarma Pharmaceuticals, visit: http://www.rafarma.com

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

RELATED LINKS
Website: www.Rafarma.com
Facebook: www.facebook.com/Rafarmainfo
Twitter: www.twitter.com/Rafarmainfo

Contact:
David Anderson
1-801-210-7135
info@rafarma.com


'/>"/>
SOURCE Rafarma Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
2. Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
3. Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli Lilly ... William Sansum Diabetes Center have established a research collaboration ... diabetes through enhanced research, education and care. ... bears a disproportionate weight on Latino families in ... Kerr , M.D., FRCPE, director of Innovation and Research ...
(Date:3/23/2017)... LONDON , March 23, 2017 ... latest Pharmaceutical and Healthcare disease pipeline guide Primary ... overview of the Primary Hyperoxaluria (Genito Urinary System ... is a rare condition characterized by recurrent kidney ... of a substance called oxalate. Symptoms include blood ...
(Date:3/23/2017)... Texas , March 23, 2017  Digital ... www.digitalpharmacist.com ), a rapidly growing digital health ... a mobile app that allows patients to manage ... multi-store locations such as Denver Health Pharmacy, USave ... The acquisition helps Digital Pharmacist accelerate its product ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . ... for the product – with nearly 2,000 consumers (and counting) already backing the ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate ... historical facts, cultural practices, goods, services, and societal issues tend to appreciate and love ... the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “End Time ... the salient events will interrelate. “End Time GPS” is the creation of published ... explosives expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
Breaking Medicine News(10 mins):